Name
Product Theater: Treatment Approaches for Resectable Gastric / Gastroesophageal Junction Cancers or Unresectable Hepatocellular Carcinoma
Speakers
Content Presented On Behalf Of:
Astra Zeneca
Session Type
Product Theater
Date
Wednesday, March 4, 2026
Start Time
11:30 AM
End Time
12:20 PM
Location
Prince Georges Exhibit Hall D
Learning Outcomes
• Understand IMFINZI-Based Indications in Certain GI Cancers
• Outline MATTERHORN: A Practice-Changing Advancement for Resectable GC/GEJC
• Summarize HIMALAYA: Primary Analysis, 5-Year, and 6-Year Post-Hoc Analysis for uHCC
• Describe Important Safety Information for IMFINZI and IMJUDO
• Identify Related Resources and Support
• Outline MATTERHORN: A Practice-Changing Advancement for Resectable GC/GEJC
• Summarize HIMALAYA: Primary Analysis, 5-Year, and 6-Year Post-Hoc Analysis for uHCC
• Describe Important Safety Information for IMFINZI and IMJUDO
• Identify Related Resources and Support
CE/CME Session
Non-CE Session
Session Currently Live
Description
This presentation discusses perioperative IMFINZI (durvalumab) in combination with FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel), followed by adjuvant IMFINZI alone, for the treatment of resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), along with IMFINZI + IMJUDO (tremelimumab-actl) for the treatment of unresectable hepatocellular carcinoma (uHCC). Key considerations in choosing a treatment option for these cancers will also be discussed.